Compounds for the treatment of mTOR pathway related diseases

A method for the treatment of one or more mTOR pathway related diseases, the method comprising administering a therapeutically effective amount of a compound of formula (I):

• or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof, wherein
• i) R1 is alkyl, —CF3 or CN, R4 is selected from H, alkyl, halogen, alkoxy, —CF3, —OCF3, —SO2—CF3, —SO—CF3 or —S—CF3 and R5 is independently selected from H, alkyl, halogen, —CF3 or —CN;
• or
• ii) R1 is selected from H or halogen, R4 is H, halogen, —S—CF3, —SOCF3 or —SO2CF3, and
• R5 is independently selected from H, halogen, or —CN;
• R2 and R3 are each independently selected from H, alkyl, halogen, —CF3 or —CN;
• R6 is independently selected from H, alkyl, halogen, alkoxy, —CF3, —OCF3, —SO2CF3, —SOCF3 or —SCF3;
• X is heteroatom, N(alkyl) or NH;
• and
• n is 1 to 20;
• thereby treating the mTOR pathway related disease, wherein the mTOR pathway related disease is cancer selected from bladder cancer, kidney cancer, liver cancer, lung cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, stomach cancer, thyroid cancer, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma, Burkett's lymphoma, myelodysplastic syndrome, rhabdomyosarcoma, astrocytoma, neuroblastoma, schwannoma, seminoma, teratocarcinoma, osteosarcoma, or Kaposi's sarcoma.